nference’s Post

nference is proud to announce a strategic research alliance with Takeda, aimed at advancing precision medicine in the treatment of Inflammatory Bowel Disease (#IBD). Introducing Project #SUCCINCT (Systematic UC & Crohn’s INformatics Clinical Toolkit), an innovative initiative leveraging our advanced artificial intelligence (#AI) capabilities to analyze de-identified electronic health records. This collaboration seeks to identify personalized treatment approaches, thereby improving patient care for those affected by IBD. IBD, which includes Crohn’s disease and ulcerative colitis, is a chronic and debilitating condition affecting millions globally. The complexity and variability of IBD pose significant challenges in managing and treating the disease. Identifying effective treatments is crucial for improving the quality of life for patients, reducing healthcare costs, and minimizing the long-term complications associated with the disease. Project SUCCINCT aims to address these challenges by providing more targeted and effective therapeutic options through AI-driven insights. "This initiative will leverage our state-of-the-art AI-enabled platform to unlock previously undiscovered insights and information that will help facilitate more precise and targeted interventions with the disease.” - Maulik Nanavaty, President of Ventures at nference and CEO at Anumana. We are excited about the potential of this collaboration to transform the landscape of IBD treatment and look forward to the advancements it will bring. #PrecisionMedicine #RealWorldEvidence #IBD #nference #Takeda Learn more: https://lnkd.in/eWFzPYPc